EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

NSAIDs do not reduce severity among post-ERCP pancreatitis patients

Bara El Kurdi, Zaid Imam, Abdulrahman Abonofal, Sumbal Babar, Pir Shah, Rahul Pannala, Georgios Papachristou, Juan Echavarria, Sailaja Pisipati, Sarah Jahangir, Prasad Rajalingamgari, Yu-Hui H Chang und 1 weitere

Pancreatology · 2024-02 · 24 (1) · 14-23

DOI: 10.1016/j.pan.2023.11.003 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pancreatology, 2024-02. Verfasst von Bara El Kurdi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine East Tennessee State University, Johnson City, TN, USA; Division of Gastroenterology and Hepatology, University of Te…. Hauptthemen laut MEDLINE: Diclofenac, Pancreatitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, US Office of Congressionally Directed Medical Research Programs, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Non-steroidal anti-inflammatory drugs (NSAIDs) are the most studied chemoprophylaxis for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). While previous systematic reviews have shown NSAIDs reduce PEP, their impact on moderate to severe PEP (MSPEP) is unclear. We conducted a systematic review and meta-analysis to understand the impact of NSAIDs on MSPEP among patients who developed PEP. We later surveyed physicians' understanding of that impact. DESIGN: A systematic search for randomized trials using NSAIDs for PEP prevention was conducted. Pooled-prevalence and Odds-ratio of PEP, MSPEP were compared between treated vs. control groups. Analysis was performed using R software. Random-effects model was used for all variables. Physicians were surveyed via email before and after reviewing our results. RESULTS: 7688 patients in 25 trials were included. PEP was significantly reduced to 0.598 (95%CI, 0.47-0.76) in the NSAIDs group. Overall burden of MSPEP was reduced among all patients undergoing ERCP: OR 0.59 (95%CI, 0.42-0.83). However, NSAIDs didn't affect the proportion of MSPEP among those who developed PEP (p = 0.658). Rectal Indomethacin and diclofenac reduced PEP but not MSPEP. Efficacy didn't vary by risk, timing of administration, or bias-risk. Survey revealed a change in the impression of the effect of NSAIDs on MSPEP after reviewing our results. CONCLUSIONS: Rectal diclofenac or indomethacin before or after ERCP reduce the overall burden of MSPEP by reducing the pool of PEP from which it can arise. However, the proportion of MSPEP among patients who developed PEP is unaffected. Therefore, NSAIDs prevent initiation of PEP, but do not affect severity among those that develop PEP. Alternative modalities are needed to reduce MSPEP among patients who develop PEP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiclofenacPancreatitisHumansCholangiopancreatography, Endoscopic RetrogradeAdministration, RectalAnti-Inflammatory Agents, Non-SteroidalIndomethacin

Substanzen

DiclofenacAnti-Inflammatory Agents, Non-SteroidalIndomethacin

Autor:innen und Institutionen

  • Department of Internal Medicine East Tennessee State University, Johnson City, TN, USA; Division of Gastroenterology and Hepatology, University of Texas Health at San Antonio, TX, USA. Electronic address: Belkurdi@caril…
  • Division of Gastroenterology and Hepatology, William Beaumont Hospital, Royal Oak, MI, USA.
  • Department of Internal Medicine East Tennessee State University, Johnson City, TN, USA.
  • Division of Gastroenterology and Hepatology, University of Texas Health at San Antonio, TX, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
  • Division of Gastroenterology and Hepatology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Förderung

  • NIDDK NIH HHS
  • US Office of Congressionally Directed Medical Research Programs
  • U.S. Department of Defense
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

El Kurdi, B., Imam, Z., Abonofal, A., Babar, S., Shah, P., Pannala, R., Papachristou, G., Echavarria, J., Pisipati, S., Jahangir, S., Rajalingamgari, P., Chang, Y. H., & Singh, V. P. (2024). NSAIDs do not reduce severity among post-ERCP pancreatitis patients. Pancreatology, 24(1), 14-23. https://doi.org/10.1016/j.pan.2023.11.003

Vancouver

El Kurdi B, Imam Z, Abonofal A, Babar S, Shah P, Pannala R, et al. NSAIDs do not reduce severity among post-ERCP pancreatitis patients. Pancreatology. 2024;24(1):14-23. doi:10.1016/j.pan.2023.11.003

BibTeX
@article{ElKurdi2024,
  author = {El Kurdi, Bara and Imam, Zaid and Abonofal, Abdulrahman and Babar, Sumbal and Shah, Pir and Pannala, Rahul and Papachristou, Georgios and Echavarria, Juan and Pisipati, Sailaja and Jahangir, Sarah and Rajalingamgari, Prasad and Chang, Yu-Hui H and Singh, Vijay P},
  title = {NSAIDs do not reduce severity among post-ERCP pancreatitis patients},
  journal = {Pancreatology},
  year = {2024},
  volume = {24},
  number = {1},
  pages = {14--23},
  doi = {10.1016/j.pan.2023.11.003}
}
Kostenlos starten →